FDA Approves INLEXZO™, the First Drug-Releasing System for Bladder Cancer
- SSCTR Exco
- Oct 12
- 1 min read
Published on LinkedIn (via Spencer Knight)
The FDA has approved INLEXZO™ (gemcitabine intravesical system) from Johnson & Johnson, marking the first and only sustained drug-releasing treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with CIS. This innovation offers a bladder-sparing alternative for patients who previously faced surgical removal as their only option.
👉 Read the full post: Huge News in Bladder Cancer: FDA Approves INLEXZO™
Disclaimer
Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.
Comments